PE20121613A1 - Derivados de quinolina amida como moduladores alostericos positivos de receptores m1 - Google Patents
Derivados de quinolina amida como moduladores alostericos positivos de receptores m1Info
- Publication number
- PE20121613A1 PE20121613A1 PE2012000830A PE2012000830A PE20121613A1 PE 20121613 A1 PE20121613 A1 PE 20121613A1 PE 2012000830 A PE2012000830 A PE 2012000830A PE 2012000830 A PE2012000830 A PE 2012000830A PE 20121613 A1 PE20121613 A1 PE 20121613A1
- Authority
- PE
- Peru
- Prior art keywords
- quinoline
- alkyl
- receptors
- halogen
- derivatives
- Prior art date
Links
- -1 OF QUINOLINE AMIDE Chemical class 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE QUINOLINA DE FORMULA (I), DONDE X1 ES N O N-O; X2-X3 ES -CH2-CH2-, -O-CH2, -CH2-O- O CH2; X4, X5, X6 Y X7 SON N, N-O, CH, O; R1 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R2A Y R2B SON H, OH, HALOGENO, JUNTOS FORMAN =O; R3 ES HALOGENO, O-ALQUILO C1-C6, S-ALQUILO C1-C6, ENTRE OTROS; R4 ES OH, HALOGENO, ALQUILO C1-C6, O-ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-[(6-CLOROPIRIDIN-3-IL)METIL]-N-[(1S,2S)-2-HIDROXICICLOHEXIL]QUINOLINA-2-CARBOXAMIDA, N-[(1S,2S)-2-HIDROXICICLOHEXIL]-4-[(6-METILPIRIDIN-3-IL)METIL]QUINOLINA-2-CARBOXAMIDA, N-[(1S,2S)-2-HIDROXICICLOHEXIL]-4-(PIRIDIN-3-ILMETIL)QUINOLINA-2-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES ALOSTERICOS POSITIVOS DE LOS RECEPTORES M1 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS TALES COMO LA ENFERMEDAD DE ALZHEIMER, ESQUIZOFRENIA, TRASTORNOS DEL DOLOR O DEL SUENO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28753509P | 2009-12-17 | 2009-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121613A1 true PE20121613A1 (es) | 2012-12-02 |
Family
ID=44305688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000830A PE20121613A1 (es) | 2009-12-17 | 2010-12-13 | Derivados de quinolina amida como moduladores alostericos positivos de receptores m1 |
Country Status (41)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| SG183265A1 (en) * | 2010-02-11 | 2012-09-27 | Univ Northwestern | Secondary structure stabilized nmda receptor modulators and uses thereof |
| KR101698250B1 (ko) | 2010-05-17 | 2017-01-19 | 포럼 파마슈티칼즈 인크. | (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태 |
| EP2582676B1 (en) | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| WO2012158474A1 (en) * | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
| EP2821401B1 (en) | 2012-03-02 | 2020-09-09 | Takeda Pharmaceutical Company Limited | Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor |
| RU2635522C2 (ru) | 2012-05-08 | 2017-11-13 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
| JP6211530B2 (ja) | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| TW201512197A (zh) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| WO2015044072A1 (en) * | 2013-09-27 | 2015-04-02 | F. Hoffmann-La Roche Ag | Indol and indazol derivatives |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| MX2016008536A (es) * | 2014-01-22 | 2016-09-26 | Hoffmann La Roche | Derivados de fluoro-naftilo. |
| EP3156397B1 (en) * | 2014-06-13 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| EA035465B1 (ru) | 2015-06-09 | 2020-06-22 | Байер Фарма Акциенгезельшафт | 7-замещенные 1-арил-нафтиридин-3-амиды карбоновой кислоты в качестве положительных аллостерических модуляторов мускаринового рецептора m2, способ их получения, их применение для лечения и/или профилактики заболеваний и лекарственное средство, содержащее эти соединения |
| KR102068237B1 (ko) * | 2015-09-10 | 2020-02-11 | 수벤 라이프 사이언시스 리미티드 | 무스카린 m1 수용체 양성 알로스테릭 조절제로서 플루오로인돌 유도체 |
| WO2017099969A1 (en) * | 2015-12-10 | 2017-06-15 | Merck Sharp & Dohme Corp. | Tetrahydroquinoxaline m1 receptor positive allosteric modulators |
| KR20180110132A (ko) * | 2016-02-16 | 2018-10-08 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 |
| WO2017151449A1 (en) * | 2016-03-04 | 2017-09-08 | Merck Sharp & Dohme Corp. | M1 receptor positive allosteric modulator compounds and methods of use thereof |
| CN109689654A (zh) | 2016-07-11 | 2019-04-26 | 拜耳医药股份有限公司 | 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途 |
| KR102017786B1 (ko) | 2016-09-02 | 2019-09-03 | 수벤 라이프 사이언시스 리미티드 | 무스카린 m1 수용체 포지티브 알로스테릭 조절제 |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| US10899759B2 (en) | 2016-09-30 | 2021-01-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| EA035599B1 (ru) * | 2017-04-13 | 2020-07-14 | Сувен Лайф Сайенсиз Лимитед | Позитивные аллостерические модуляторы мускариновых m1-рецепторов |
| DK3643718T3 (da) * | 2017-06-20 | 2023-11-06 | Takeda Pharmaceuticals Co | Heterocyklisk forbindelse og anvendelse deraf som positiv allosterisk modulator af den kolinerge muskarin m1-receptor |
| AU2018289939B2 (en) * | 2017-06-20 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2019082140A1 (en) | 2017-10-27 | 2019-05-02 | Suven Life Sciences Limited | POLYCYCLIC AMIDES AS POSITIVE ALLOSTERIC MODULATORS OF M1 MUSCARINIC RECEPTOR |
| JP7443238B2 (ja) * | 2018-09-28 | 2024-03-05 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2020067457A1 (ja) | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| BR112021007168A2 (pt) | 2018-10-17 | 2021-08-10 | Suven Life Sciences Limited | derivados de pirrolo-piridazina como moduladores alostericos positivos do receptor muscarínico m1 |
| US12065433B2 (en) | 2018-10-24 | 2024-08-20 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) * | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| KR20030027094A (ko) * | 2000-08-29 | 2003-04-03 | 야마노우치세이야쿠 가부시키가이샤 | 신규 에스테르 또는 아미드 유도체 |
| EP1596867A4 (en) | 2003-02-19 | 2006-03-22 | Merck & Co Inc | TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR |
| EP1601357A4 (en) * | 2003-03-10 | 2007-10-03 | Schering Corp | HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS |
| SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| DE602004025508D1 (de) * | 2003-12-23 | 2010-03-25 | Serodus As | Modulatoren von peripheren 5-ht-rezeptoren |
| US20070185090A1 (en) * | 2004-03-17 | 2007-08-09 | Jakob Busch-Petersen | Muscarinic acetylchoine receptor antagonists |
| CN101321733A (zh) * | 2005-12-05 | 2008-12-10 | 默克公司 | 喹诺酮m1受体阳性变构调节剂 |
| ATE475650T1 (de) | 2005-12-05 | 2010-08-15 | Merck Sharp & Dohme | Positive allosterische chinolon-m1- rezeptormodulatoren |
| PE20091036A1 (es) * | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
| WO2009117283A2 (en) * | 2008-03-21 | 2009-09-24 | Merck & Co., Inc. | Quinolizidinone m1 receptor positive allosteric modulators |
| US8557832B2 (en) | 2008-11-20 | 2013-10-15 | Merck Sharp & Dohme Corp. | Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators |
| US8486946B2 (en) | 2009-02-23 | 2013-07-16 | Merck Sharp & Dohme Corp. | Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators |
| US8293744B2 (en) | 2009-04-20 | 2012-10-23 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators |
| EP2473048B1 (en) | 2009-08-31 | 2015-03-25 | Merck Sharp & Dohme Corp. | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| EP2490692B1 (en) | 2009-10-21 | 2016-11-16 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| WO2011075371A1 (en) | 2009-12-14 | 2011-06-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
| WO2011084371A1 (en) | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
| EP2575454B1 (en) | 2010-05-28 | 2018-08-29 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide m1 receptor positive allosteric modulators |
| EP2582676B1 (en) | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| US8557992B2 (en) | 2010-06-15 | 2013-10-15 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators |
| WO2012158474A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
-
2010
- 2010-12-13 WO PCT/US2010/060007 patent/WO2011084368A1/en not_active Ceased
- 2010-12-13 PH PH1/2012/501222A patent/PH12012501222A1/en unknown
- 2010-12-13 EP EP10841821.1A patent/EP2512243B1/en active Active
- 2010-12-13 ME MEP-2016-106A patent/ME02421B/me unknown
- 2010-12-13 US US13/515,724 patent/US9199939B2/en active Active
- 2010-12-13 ES ES10841821.1T patent/ES2575154T3/es active Active
- 2010-12-13 SG SG2012044095A patent/SG181719A1/en unknown
- 2010-12-13 PT PT108418211T patent/PT2512243E/pt unknown
- 2010-12-13 MX MX2012007013A patent/MX336774B/es unknown
- 2010-12-13 RS RS20160369A patent/RS54798B1/sr unknown
- 2010-12-13 PE PE2012000830A patent/PE20121613A1/es not_active Application Discontinuation
- 2010-12-13 MA MA35061A patent/MA33920B1/fr unknown
- 2010-12-13 NZ NZ600674A patent/NZ600674A/xx not_active IP Right Cessation
- 2010-12-13 KR KR1020127015521A patent/KR101494059B1/ko not_active Expired - Fee Related
- 2010-12-13 BR BR112012014180A patent/BR112012014180A2/pt active Search and Examination
- 2010-12-13 CN CN201080057292.2A patent/CN102651970B/zh not_active Expired - Fee Related
- 2010-12-13 DK DK10841821.1T patent/DK2512243T3/en active
- 2010-12-13 HU HUE10841821A patent/HUE029734T2/en unknown
- 2010-12-13 EA EA201290519A patent/EA022494B1/ru not_active IP Right Cessation
- 2010-12-13 PL PL10841821.1T patent/PL2512243T3/pl unknown
- 2010-12-13 HR HRP20160574TT patent/HRP20160574T1/hr unknown
- 2010-12-13 UA UAA201208772A patent/UA106406C2/ru unknown
- 2010-12-13 GE GEAP201012786A patent/GEP201606506B/en unknown
- 2010-12-13 AU AU2010340142A patent/AU2010340142B2/en not_active Ceased
- 2010-12-13 SI SI201031184A patent/SI2512243T1/sl unknown
- 2010-12-13 JP JP2012544670A patent/JP5651708B2/ja not_active Expired - Fee Related
- 2010-12-13 CA CA2782347A patent/CA2782347C/en not_active Expired - Fee Related
- 2010-12-16 TW TW099144262A patent/TWI412525B/zh not_active IP Right Cessation
- 2010-12-17 AR ARP100104723A patent/AR079510A1/es unknown
-
2012
- 2012-05-17 TN TNP2012000231A patent/TN2012000231A1/en unknown
- 2012-06-03 IL IL220130A patent/IL220130A0/en unknown
- 2012-06-12 ZA ZA2012/04313A patent/ZA201204313B/en unknown
- 2012-06-14 CL CL2012001605A patent/CL2012001605A1/es unknown
- 2012-06-14 HN HN2012001265A patent/HN2012001265A/es unknown
- 2012-06-15 NI NI201200107A patent/NI201200107A/es unknown
- 2012-06-15 CR CR20120327A patent/CR20120327A/es unknown
- 2012-06-15 CO CO12101581A patent/CO6551729A2/es unknown
- 2012-06-15 GT GT201200201A patent/GT201200201A/es unknown
- 2012-06-15 DO DO2012000167A patent/DOP2012000167A/es unknown
- 2012-06-19 EC ECSP12011983 patent/ECSP12011983A/es unknown
-
2015
- 2015-11-18 US US14/945,005 patent/US20160075656A1/en not_active Abandoned
-
2016
- 2016-07-05 CY CY20161100625T patent/CY1117726T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121613A1 (es) | Derivados de quinolina amida como moduladores alostericos positivos de receptores m1 | |
| PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
| PE20190913A1 (es) | Derivados aromaticos de sulfonamida | |
| AR078944A1 (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
| PE20120113A1 (es) | Nuevos derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| WO2009082268A3 (ru) | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
| PE20071254A1 (es) | Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion | |
| PE20121158A1 (es) | Derivados de feniletinilo como moduladores alostericos positivos (map) | |
| CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| PE20070712A1 (es) | Sulfonamidas biciclicas como moduladores del receptor de glucocorticoides en el tratamiento de enfermedades inflamatorias | |
| PE20080074A1 (es) | Derivados de amida como agentes inhibidores de la quinasa c-fms | |
| PE20090435A1 (es) | Inhibidores de tetrahidropiranocromeno de gamma secretasa | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20090892A1 (es) | MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3 | |
| PE20110703A1 (es) | Acidos naftilaceticos | |
| CY1116452T1 (el) | Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης | |
| PE20150629A1 (es) | Derivados de etinilo como moduladores de la actividad del receptor de mglur5 | |
| PE20081657A1 (es) | Derivados de ftalazina como antagonistas de los receptores de histamina h1 | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal | |
| PE20120881A1 (es) | Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6 | |
| HRP20170025T1 (hr) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| PE20091431A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |